We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Jardiance

News List

Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease pharmatimes
July 16, 2018
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance pharmatimes
June 06, 2018
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim's Jardiance.
Jardiance® (empagliflozin) analysis reinforces established safety profile lilly
June 15, 2017
An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets...

Previous page 1 2 Next page